Payment overview · 2025
General Payments
$305.59
12 reported records · 5 companies
Healthcare provider profile · identity verified
Francisco A Reytor, MD
Allopathic & Osteopathic Physicians|General Practice · CORAL GABLES, FL · NPI 1295714376
Verified facts
What the public records show
CMS Open Payments records show Francisco A Reytor, MD received $305.59 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 60.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $184.20 | 60.3% | 7 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $38.18 | 12.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.75 | 11.0% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $29.05 | 9.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.41 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $305.59 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $184.20 | 7 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $38.18 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $33.75 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
115 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 848 | 220 |
| Losartan Potassium | Losartan Potassium | 491 | 107 |
| Gabapentin | Gabapentin | 425 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 405 | 104 |
| Metformin Hcl | Metformin Hcl | 392 | 95 |
| Lisinopril | Lisinopril | 336 | 84 |
| Famotidine | Famotidine | 333 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 88 |
| Montelukast Sodium | Montelukast Sodium | 280 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 71 |
| Azithromycin | Azithromycin | 271 | 165 |
| Furosemide | Furosemide | 270 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 256 | 68 |
| Omeprazole | Omeprazole | 252 | 63 |
| Trazodone Hcl | Trazodone Hcl | 252 | 59 |
| Mirtazapine | Mirtazapine | 209 | 51 |
| Eliquis | Apixaban | 200 | 38 |
| Ibuprofen | Ibuprofen | 198 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 181 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 177 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 51 |
| Meloxicam | Meloxicam | 168 | 93 |
| Temazepam | Temazepam | 167 | 25 |
| Alprazolam | Alprazolam | 160 | 37 |
| Ketoconazole | Ketoconazole | 149 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 37 |
| Carvedilol | Carvedilol | 146 | 32 |
| Memantine Hcl | Memantine Hcl | 145 | 28 |
| Simvastatin | Simvastatin | 143 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 134 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 129 | 44 |
| Ssd | Silver Sulfadiazine | 126 | 34 |
| Doxazosin Mesylate | Doxazosin Mesylate | 122 | 42 |
| Mupirocin | Mupirocin | 117 | 62 |
| Linzess | Linaclotide | 115 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 111 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 31 |
| Ammonium Lactate | Ammonium Lactate | 102 | 22 |
| Labetalol Hcl | Labetalol Hcl | 97 | 16 |
| Glimepiride | Glimepiride | 94 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 20 |
| Alendronate Sodium | Alendronate Sodium | 92 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 92 | 62 |
| Valsartan | Valsartan | 91 | 18 |
| Folic Acid | Folic Acid | 89 | 17 |
| Donepezil Hcl | Donepezil Hcl | 88 | 25 |
| Potassium Chloride | Potassium Chloride | 86 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 17 |
| Nifedipine Er | Nifedipine | 85 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 21 |
| Sertraline Hcl | Sertraline Hcl | 84 | 24 |
| Clonidine Hcl | Clonidine Hcl | 83 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 60 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 35 |
| Lorazepam | Lorazepam | 81 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 34 |
| Levofloxacin | Levofloxacin | 76 | 62 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 14 |
| Glipizide | Glipizide | 70 | 21 |
| Methylprednisolone | Methylprednisolone | 69 | 50 |
| Silver Sulfadiazine | Silver Sulfadiazine | 69 | 21 |
| Latanoprost | Latanoprost | 67 | 15 |
| Lactulose | Lactulose | 66 | 15 |
| Dutasteride | Dutasteride | 61 | 15 |
| Risperidone | Risperidone | 61 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 60 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | suppressed |
| Metronidazole | Metronidazole | 54 | 35 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 53 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 51 | 22 |
| Tramadol Hcl | Tramadol Hcl | 51 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 12 |
| Nystatin | Nystatin | 50 | 28 |
| Cefdinir | Cefdinir | 49 | 34 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 15 |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Jardiance | Empagliflozin | 48 | 13 |
| Telmisartan | Telmisartan | 47 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 33 |
| Allopurinol | Allopurinol | 45 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 11 |
| Midodrine Hcl | Midodrine Hcl | 45 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 28 |
| Pentoxifylline | Pentoxifylline | 43 | 11 |
| Prednisone | Prednisone | 43 | 16 |
| Clonazepam | Clonazepam | 42 | 11 |
| Tadalafil | Tadalafil | 42 | 14 |
| Finasteride | Finasteride | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 21 |
| Novolog Flexpen | Insulin Aspart | 41 | 11 |
| Digoxin | Digoxin | 40 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Benzonatate | Benzonatate | 39 | 31 |
| Enalapril Maleate | Enalapril Maleate | 39 | 11 |
| Atenolol | Atenolol | 38 | 14 |
| Glyburide | Glyburide | 38 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 38 | 12 |
| Hydrocortisone | Hydrocortisone | 37 | 19 |
| Ofloxacin | Ofloxacin | 37 | 26 |
| Ozempic | Semaglutide | 37 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | 14 |
| Amoxicillin | Amoxicillin | 34 | 20 |
| Cephalexin | Cephalexin | 33 | 28 |
| Methocarbamol | Methocarbamol | 33 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Baclofen | Baclofen | 31 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 31 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Clotrimazole | Clotrimazole | 29 | 11 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Anastrozole | Anastrozole | 24 | suppressed |
| Ciclopirox | Ciclopirox | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | 13 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 21 | 20 |
| Budesonide | Budesonide | 20 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 11 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 11 |
| Pentips Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Erythromycin | Erythromycin Base | 17 | 15 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | 12 |
| Fluconazole | Fluconazole | 14 | 11 |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | 11 |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Theophylline | Theophylline Anhydrous | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $305.59 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, LINZESS, Natroba, OTEZLA, REPATHA, Spinosad, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error